Herman James L 4

What Happened James L. Herman, Vice President and Chief Compliance Officer of Cumberland Pharmaceuticals (CPIX), was granted 2,500 shares on March 18, 2026. The Form 4 reports the acquisition as an award (transaction code A) at a reported value of $2.80 per share, totaling $7,000. This was an equity award/grant (a derivative acquisition), not an open-market purchase or sale.

Key Details

• Transaction date and price: 2026-03-18; 2,500 shares at $2.80 each (total value $7,000).
• Shares owned after transaction: Not disclosed in the provided filing.
• Transaction type: Code A — award/grant (derivative acquisition).
• Filing date: 2026-03-20 (filed two days after the transaction; appears timely under Form 4 reporting rules).
• No footnotes or 10b5-1/tax-withholding details were provided in the transaction data given.

Context An "A" code on Form 4 indicates the insider received an equity award (such as a stock grant or restricted stock unit), which may be subject to vesting or other conditions; the filing does not specify vesting terms. Awards are typically compensation-related and do not necessarily reflect immediate buying or selling sentiment by the insider. The reported dollar value here ($7,000) is relatively modest in size.